CL2024002500A1 - Inhibidores de proteínas de unión a emopamilo y usos de estos - Google Patents

Inhibidores de proteínas de unión a emopamilo y usos de estos

Info

Publication number
CL2024002500A1
CL2024002500A1 CL2024002500A CL2024002500A CL2024002500A1 CL 2024002500 A1 CL2024002500 A1 CL 2024002500A1 CL 2024002500 A CL2024002500 A CL 2024002500A CL 2024002500 A CL2024002500 A CL 2024002500A CL 2024002500 A1 CL2024002500 A1 CL 2024002500A1
Authority
CL
Chile
Prior art keywords
inhibitors
binding proteins
emopamil binding
ebp
emopamil
Prior art date
Application number
CL2024002500A
Other languages
English (en)
Inventor
Gilfillan Rab
Himmelbauer Martin
Gonzalez Lopez De Turiso Felix
Yin-Shiang Lin Edward
Pattaropong Vatee
Xin Zhili
Chen Teyu
H Jones John
BANSAL Nupur
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CL2024002500A1 publication Critical patent/CL2024002500A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I): (I), o sales farmacéuticamente aceptables de estos, que son útiles para la 5 inhibición de EBP y en el tratamiento de una variedad de afecciones o enfermedades mediadas por EBP, tales como esclerosis múltiple.
CL2024002500A 2022-02-25 2024-08-21 Inhibidores de proteínas de unión a emopamilo y usos de estos CL2024002500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263314095P 2022-02-25 2022-02-25

Publications (1)

Publication Number Publication Date
CL2024002500A1 true CL2024002500A1 (es) 2025-01-10

Family

ID=85775879

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002500A CL2024002500A1 (es) 2022-02-25 2024-08-21 Inhibidores de proteínas de unión a emopamilo y usos de estos

Country Status (18)

Country Link
US (1) US20250171463A1 (es)
EP (1) EP4482587A1 (es)
JP (1) JP2025508839A (es)
KR (1) KR20240165360A (es)
CN (1) CN119156392A (es)
AR (1) AR128585A1 (es)
AU (1) AU2023224082A1 (es)
CA (1) CA3252730A1 (es)
CL (1) CL2024002500A1 (es)
CO (1) CO2024012770A2 (es)
CR (1) CR20240394A (es)
IL (1) IL315110A (es)
JO (1) JOP20240183A1 (es)
MX (1) MX2024010402A (es)
PE (1) PE20250665A1 (es)
TW (1) TW202345794A (es)
UY (1) UY40160A (es)
WO (1) WO2023164063A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049275A1 (en) * 2023-08-25 2025-03-06 Biogen Ma Inc. Emopamil-binding protein inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10082496B2 (en) * 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
TW202309006A (zh) * 2021-04-30 2023-03-01 西班牙商塔拉森斯調節公司 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物

Also Published As

Publication number Publication date
CO2024012770A2 (es) 2024-12-09
CA3252730A1 (en) 2023-08-31
JOP20240183A1 (ar) 2024-08-14
JP2025508839A (ja) 2025-04-10
AU2023224082A1 (en) 2024-08-29
KR20240165360A (ko) 2024-11-22
WO2023164063A1 (en) 2023-08-31
CR20240394A (es) 2025-02-14
CN119156392A (zh) 2024-12-17
TW202345794A (zh) 2023-12-01
PE20250665A1 (es) 2025-03-04
US20250171463A1 (en) 2025-05-29
UY40160A (es) 2023-09-15
EP4482587A1 (en) 2025-01-01
IL315110A (en) 2024-10-01
AR128585A1 (es) 2024-05-22
MX2024010402A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2021003202A1 (es) Compuestos de pirrolidina
JOP20220282A1 (ar) مركبات مفيدة لتثبيط كيناز ret
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
CL2025000445A1 (es) Inhibidores de kif18a y usos de estos
CO2021014210A2 (es) Compuestos de pirrol
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2025002808A1 (es) Compuestos derivados de acilsulfonamida inhibidores de kat6a y uso para tratar cáncer.
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
AR131735A1 (es) Agentes terapéuticos
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
UY40353A (es) Inhibidores de proteína de unión a emopamil y usos de estos
UY38133A (es) Nuevos inhibidores de cdk8/19
AR133607A1 (es) Inhibidores de la proteína de unión al emopamilo y usos de estos
MX2024012198A (es) Compuestos y metodos para tratar canceres